ClinicalTrials.gg
Drug

Tapinarof clinical trials

Also written DMVT-505 and WBI-1001.

studies test it
34
open now
5
in phase 3
12
first study started
2008

How each study uses tapinarof is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tapinarof studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 May 2022 · VTAMA · NDA 215272 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tapinarof cream, 1%
9
Tapinarof
7
GSK2894512 1% Cream
4
Benvitimod Cream
3
Vtama® (Tapinarof) Cream, 1%
2

Brand

VTAMA
1

Development codes

DMVT-505
8
WBI-1001
4
OG-0505
1
GSK2894512A
1
GSK28994512
1
STI-1001
1

Other names

Benvitimod
1

Studies by the year they started

34 studies that test it; most in 2021 (6)

Studies that test tapinarof, by start year
YearStudies
20081
20091
20101
20131
20154
20171
20181
20194
20216
20223
20232
20243
20253
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
6
Phase 2
10
Phase 3
12
Phase 4
6
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 24 · Other 10

Organon and Co (12) · GlaxoSmithKline (6) · Welichem Biotech Inc. (3) · Peking University People's Hospital (3) · Indiana University (1) · Sun Pharmaceutical Industries, Inc. (1) · Teva Pharmaceuticals USA (1) · Psoriasis Treatment Center of Central New Jersey (1)

Often tested with

Tested in the same studies.

Betamethasone dipropionate (1) · Betamethasone (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 2 in phase 3

Studies that test tapinarof, phase 3 first.

Studies

Open first, then newest update. How each study uses tapinarof is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 34

See all 34 studies that test tapinarof →

Codes

What other systems call tapinarof · ClinicalTrials.gg INT006049

  • MeSH (NLM) C571829tapinarofConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 84HW7D0V04TAPINAROFConfirmed FDA, NLM, Wikidata
  • RxNorm 2602286One source FDA
  • Wikidata Q76386711tapinarofConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152511TapinarofOne source FDA
  • DrugBank DB06083One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.